SOVREMENNYE VOZMOZhNOSTI TERAPII GASTROINTESTINAL'NYKh STROMAL'NYKh OPUKhOLEY: KLINIChESKOE NABLYuDENIE


Citar

Texto integral

Resumo

Обсуждаются возможности лечения локализованных и распространенных форм гастроинтестинальных стромальных опухолей (GIST). Основным методом лечения локализованных опухолей является хирургический. В России после радикальных операций дополнительное лечение не назначают, больные находятся под пристальным динамическим наблюдением. Поскольку GIST не чувствительны к традиционной химиотерапии, возможности лечения больных распространенными формами GIST связаны главным образом с внедрением в клиническую практику низкомолекулярного ингибитора семейства тирозинкиназ иматиниба (Гливека). По данным клинических исследований, назначение Гливека в качестве первой линии терапии GIST позволяет добиваться высоких показателей продолжительности жизни больных без ухудшения ее качества.

Sobre autores

L Bolotina

Bibliografia

  1. Blackstein ME, Blay JY, et al. Gastrointestinal stromal tumors: consensus statement on diagnosis and treatment. Can J Gastroenterol 2006;20:157-63.
  2. Corless CL, Fletcher JA, et al. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004;22:3813-25.
  3. Demetri GD, Benjamin RS, et al. NCCN Task Force Report: management of patients with gastrointestinal stromal tumors (GIST) - update of the NCCN Clinical Practice Guidelines. J Natl Compr Canc Netw 2007;5(Suppl. 2):S1-29.
  4. Steigen SE, Eide TJ. Trends in incidence and survival of mesenchymal neoplasm of the digestive tract within a defined population of northern Norway. Apmis 2006;114:192-200.
  5. Agami A, Wunsch PH, et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 2007;31:113-20.
  6. Yuzawa S, Opatowsky Y, et al. Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor. Cell 2007;130:323-34.
  7. Heinrich MC, Corless CL, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-10.
  8. Nilsson B, Bumming P, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era. Cancer 2005;103:821-29.
  9. Edmonson JH, Marks RS, et al. Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Invest 2002;20:605-12.
  10. Gold JS, van der Zwan SM, et al. Outcome of metastatic GIST in the era before tyrosine kinase inhibitors. Ann Surg Oncol 2007;14:134-42.
  11. Demetri GD, von Mehren M, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
  12. Rankin C, von Mehren M, et al. Dose effect of imatinib in patients with metastatic GIST - phase III Sarcoma Group Study S0033 (ASCO abstract 9005) Proc Am Soc Clin Oncol 2004;22:815.
  13. Debiec-Rychter M, Sciot R, et al. KIT mutations and dose selection for imatinib with advanced gastrointestinal stromal tumors. Eur J Cancer 2006;42:1093-103.
  14. Blay JY, Le Cesne A, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: The French Sarcoma Group. J Clin Oncol 2007;25:1107-13.
  15. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors:recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-58.
  16. DeMatteo R, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. The Lancet. Published online March 19, 2009. Accessed March 2009. http://www.thelancet.com/
  17. Gleevec® (imatinib mesylate) tablets prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2009